Ascent Wealth Partners LLC Makes New $10.57 Million Investment in Eli Lilly and Company $LLY

Key Points

• Ascent Wealth Partners acquired 9,135 Eli Lilly shares worth approximately $10.57 million in the third quarter, making LLY about 1% of its portfolio. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported quarterly earnings of $8.38 per share, beating estimates by $1.98, while revenue rose 47.7% year over year to $22.97 billion. The stock opened at $1,279.29, near its 52-week high, with a market capitalization of roughly $1.20 trillion.
• Analysts maintain a broadly bullish outlook, with a consensus “Moderate Buy” rating and an average price target of $1,320.25. However, competition from Novo Nordisk, pricing and market-access pressures, and the stock’s elevated valuation remain key risks.

Ascent Wealth Partners LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,135 shares of the company's stock, valued at approximately $10,570,000. Eli Lilly and Company accounts for approximately 1.0% of Ascent Wealth Partners LLC's holdings, making the stock its 25th largest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Marshall & Sterling Wealth Advisors Inc. raised its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $42,000. Caitlin John LLC bought a new stake in Eli Lilly and Company during the second quarter worth about $64,000. IMG Wealth Management Inc. lifted its stake in Eli Lilly and Company by 500.0% during the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after purchasing an additional 50 shares during the last quarter. Finally, Whipplewood Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 213.8% in the 1st quarter. Whipplewood Advisors LLC now owns 91 shares of the company's stock worth $84,000 after purchasing an additional 62 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $1,279.29 on Tuesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock's 50 day simple moving average is $1,187.35 and its 200 day simple moving average is $1,086.38. The firm has a market cap of $1.20 trillion, a price-to-earnings ratio of 42.93, a PEG ratio of 1.71 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $809.63 and a 1 year high of $1,321.21.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business's revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A U.S. judge declined to block Eli Lilly’s advertising for its weight-loss drugs in a case brought by Novo Nordisk. The ruling supports Lilly’s ability to market its obesity treatments and represents a favorable development in the competitive GLP-1 market. US judge won't block Eli Lilly ads for weight-loss drugs
• Positive Sentiment: New clinical data for investigational lung-cancer drug olomorasib showed durable first-line activity in KRAS G12C-mutated non-small-cell lung cancer, strengthening Lilly’s pipeline beyond its obesity and diabetes franchises. New data on Lilly's investigational treatment olomorasib
• Positive Sentiment: Early Phase 1 results for Lilly’s investigational sofe-m plus bevacizumab regimen in ovarian cancer showed high response and disease-control rates without major new safety signals. Although preliminary, the data add potential long-term value to the oncology pipeline. Lilly reports strong Phase 1 ovarian cancer data
• Positive Sentiment: The board declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The announcement provides a modest signal of financial confidence, though the dividend is not likely to be the primary stock catalyst. Lilly declares fourth-quarter 2026 dividend
• Neutral Sentiment: Analysts have high expectations for the October 29 earnings report, with investors focused on demand for weight-loss drugs, prescription trends, manufacturing capacity and updated full-year guidance. A strong report could extend the rally, while any miss could prompt volatility. Wall Street has high expectations for Eli Lilly
• Negative Sentiment: Competition from Novo Nordisk and broader pricing, patent and market-access pressures remain risks. Analysts also caution that revenue could temporarily soften even as patient numbers grow, while Lilly’s elevated valuation leaves the stock sensitive to weaker-than-expected guidance. Why revenue could dip even as patients grow

Analyst Ratings Changes

Several brokerages have recently commented on LLY. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. Guggenheim raised their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 15th. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research note on Monday. Finally, Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,320.25.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last three months. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.